Sriharsha Kantamneni
Has grant
Chief Scientific Officer
United KingdomResearch Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Sriharsha Kantamneni is the Chief Scientific Officer at Haiku Therapeutics Limited in the United Kingdom. His research focuses on novel therapeutic strategies for cancer treatment, including resistance modulation in oxaliplatin-based therapies and the biological aspects of sulfonamide derivatives. He is also investigating the role of the Chemerin-CMKLR1 axis in regulating energy homeostasis.
Recent Grants
Grant: Close
ESCRT proteins as regulators of receptor trafficking and therapeutic targets in Alzheimer's disease
Open Date: 2018-05-01
Close Date: 2018-08-01
Grant: Close
Molecular mechanisms underlying chemerin receptor (CMKLR1) signalling pathways, trafficking and regulation in novel hypothalamic neuronal cell line
Open Date: 2017-12-01
Close Date: 2018-12-01
Grant: Close
The SOCS3/TBK1 interface: Development of novel therapeutics to prevent MND and neurodegeneration
Open Date: 2017-05-01
Close Date: 2017-08-01
Grant: Close
ESCRT proteins as therapeutic targets in Alzheimer's disease
Open Date: 2016-05-01
Close Date:
Grant: Close
Mechanisms regulating NMDA-mediated down-regulation of neuronal GABAB receptors in ischemia.
Open Date: 2016-03-01
Close Date:
Articles (3)
Year:
2025
Year:
2025
Year:
2022
Collaborators (3)
Gisela Helfer
Associate Professor in Physiology and Metabolism
University of Bradford
Steven D. Shnyder
University of Bradford
Helen M. Sheldrake
University of Bradford
ApplyKite TwinLearns as you applyMake your next move.
Prepare your application
Review drafts before you send them.